AbbVie
(NYSE:ABBV)
$178.00
-0.99[-0.55%]
At close: Feb 28
$178.00
0[0.00%]
After Hours: 4:20PM EDT

GET A REPORT ON ABBV SENT RIGHT TO YOUR INBOX

AbbVie Stock (NYSE:ABBV), Analyst Ratings, Price Targets, Predictions

Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are directional and typically buy, sell or hold. Price Targets are an analyst's best guess at where the stock will trade in 12 months.
Consensus Rating1
Outperform
Highest Price Target1
$195.00
Lowest Price Target1
$115.00
Consensus Price Target1
$144.31

Analyst Rating Summary1

Analyst Ratings
Sep 23
1
Oct 23
3
Nov 23
0
0
0
0
0
Dec 23
2
Jan
2
Feb
5
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Raymond James
Truist Securities
BMO Capital
Barclays
William Blair

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for AbbVie

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
02/06/2024ABBVBuy Now
AbbVie
$178.006.18%Raymond James
Gary Nachman
$181 → $189MaintainsOutperformGet Alert
02/06/2024ABBVBuy Now
AbbVie
$178.009.55%Truist Securities
Robyn Karnauskas
$180 → $195MaintainsBuyGet Alert
02/05/2024ABBVBuy Now
AbbVie
$178.006.18%Raymond James
Gary Nachman
$181 → $189MaintainsOutperformGet Alert
02/05/2024ABBVBuy Now
AbbVie
$178.009.55%BMO Capital
Evan David Seigerman
$187 → $195MaintainsOutperformGet Alert
02/05/2024ABBVBuy Now
AbbVie
$178.003.93%Barclays
Carter Gould
$175 → $185MaintainsOverweightGet Alert
01/29/2024ABBVBuy Now
AbbVie
$178.00William Blair
Tim Lugo
UpgradeMarket Perform → OutperformGet Alert
01/23/2024ABBVBuy Now
AbbVie
$178.00-1.69%Barclays
Carter Gould
$170 → $175MaintainsOverweightGet Alert
12/18/2023ABBVBuy Now
AbbVie
$178.00-12.36%HSBC
Rajesh Kumar
$167 → $156DowngradeBuy → HoldGet Alert
12/11/2023ABBVBuy Now
AbbVie
$178.00-2.81%Goldman Sachs
Chris Shibutani
→ $173UpgradeNeutral → BuyGet Alert
12/01/2023ABBVBuy Now
AbbVie
$178.001.69%Raymond James
Gary Nachman
$177 → $181MaintainsOutperformGet Alert
11/09/2023ABBVBuy Now
AbbVie
$178.00-15.73%Deutsche Bank
James Shin
→ $150Initiates → HoldGet Alert
10/30/2023ABBVBuy Now
AbbVie
$178.0010.11%Morgan Stanley
Terence Flynn
$193 → $196MaintainsOverweightGet Alert
10/30/2023ABBVBuy Now
AbbVie
$178.00-4.49%Barclays
Carter Gould
$160 → $170UpgradeEqual-Weight → OverweightGet Alert
10/11/2023ABBVBuy Now
AbbVie
$178.008.43%Morgan Stanley
Terence Flynn
$189 → $193MaintainsOverweightGet Alert
09/29/2023ABBVBuy Now
AbbVie
$178.00-0.56%Raymond James
Gary Nachman
→ $177Initiates → OutperformGet Alert
07/28/2023ABBVBuy Now
AbbVie
$178.00-4.49%Piper Sandler
Christopher Raymond
$163 → $170MaintainsOverweightGet Alert
07/25/2023ABBVBuy Now
AbbVie
$178.00William Blair
Tim Lugo
Initiates → Market PerformGet Alert
07/14/2023ABBVBuy Now
AbbVie
$178.00-6.18%HSBC
Rajesh Kumar
→ $167Initiates → BuyGet Alert
07/11/2023ABBVBuy Now
AbbVie
$178.002.25%Morgan Stanley
Terence Flynn
$182 → $182ReiteratesOverweight → OverweightGet Alert

FAQ

Q

What is the target price for AbbVie (ABBV)?

A

The latest price target for AbbVie (NYSE: ABBV) was reported by Raymond James on February 6, 2024. The analyst firm set a price target for $189.00 expecting ABBV to rise to within 12 months (a possible 6.18% upside). 25 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for AbbVie (ABBV)?

A

The latest analyst rating for AbbVie (NYSE: ABBV) was provided by Raymond James, and AbbVie maintained their outperform rating.

Q

When is the next analyst rating going to be posted or updated for AbbVie (ABBV)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AbbVie, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AbbVie was filed on February 6, 2024 so you should expect the next rating to be made available sometime around February 6, 2025.

Q

Is the Analyst Rating AbbVie (ABBV) correct?

A

While ratings are subjective and will change, the latest AbbVie (ABBV) rating was a maintained with a price target of $181.00 to $189.00. The current price AbbVie (ABBV) is trading at is $178.00, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch